BTK Inhibitor–Associated AEs Can Influence Treatment Selection in MCL

William Pearse, MD, discusses the roles of acalabrutinib and zanubrutinib in mantle cell lymphoma, as well as the adverse effect profiles of each agent.

Related Keywords

San Diego ,California ,United States ,Williamb Pearse , ,University Of California ,San Diego School Of Medicine ,San Diego School ,Nct04855695 ,William Pearse ,D ,Acalabrutinib ,Zanubrutinib ,Mantle Cell Lymphoma ,Cmcl ,